Massive Sell-Offs: These 10 Stocks Shockingly Nosedived

Page 9 of 9

1. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics slashed its share price by 44 percent last week following price target cuts from two investment companies.

In a market note, Oppenheimer significantly lowered its price target for Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to $45 from $123 previously, marking a 63-percent downside. The adjustment followed the death of a second patient from acute liver failure after taking its Elevidys treatment.

Following the news, the company temporarily halted Elevidys shipments for non-ambulatory patients and suspended its fiscal year 2025 product revenue guidance of $2.3 billion to $2.6 billion.

For its part, William Blair downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to “market perform” from “outperform” previously on expectations of lower revenue opportunities despite continued strong interest in its Elevidys treatment.

According to William Blair, there is a growing number of “uncertain variables” that it believes would deter investors from buying stocks in the coming periods.

While we acknowledge the potential of SRPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SRPT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9